Case Fatality Risk of the First Pandemic Wave of Coronavirus Disease 2019 (COVID-19) in China

Abstract

Objective To assess the case fatality risk (CFR) of COVID-19 in mainland China, stratified by region and clinical category, and estimate key time-to-event intervals. Methods We collected individual information and aggregated data on COVID-19 cases from publicly available official sources from December 29, 2019 to April 17, 2020. We accounted for right-censoring to estimate the CFR and explored the risk factors for mortality. We fitted Weibull, gamma, and lognormal distributions to time-to-event data using maximum-likelihood estimation. Results We analyzed 82,719 laboratory-confirmed cases reported in mainland China, including 4,632 deaths, and 77,029 discharges. The estimated CFR was 5.65% (95%CI: 5.50%-5.81%) nationally, with highest estimate in Wuhan (7.71%), and lowest in provinces outside Hubei (0.86%). The fatality risk among critical patients was 3.6 times that of all patients, and 0.8-10.3 fold higher than that of mild-to-severe patients. Older age (OR 1.14 per year; 95%CI: 1.11-1.16), and being male (OR 1.83; 95%CI: 1.10-3.04) were risk factors for mortality. The time from symptom onset to first healthcare consultation, time from symptom onset to laboratory confirmation, and time from symptom onset to hospitalization were consistently longer for deceased patients than for those who recovered. Conclusions Our CFR estimates based on laboratory-confirmed cases ascertained in mainland China suggest that COVID-19 is more severe than the 2009 H1N1 influenza pandemic in hospitalized patients, particularly in Wuhan. Our study provides a comprehensive picture of the severity of the first wave of the pandemic in China. Our estimates can help inform models and the global response to COVID-19.

Assessing the impact of non-pharmaceutical interventions on the transmissibility and severity of COVID-19 during the first five months in the Western Pacific Region

“…Our estimates were also lower than those in Canada and the United States [ 25 ]. Compared with the CFR observed that ranged between 7% and 12% in the original epicentre of the pandemic, Wuhan [ 26 , 27 ], our estimates were lower although the CFR in Wuhan could be substantially lower if the clinically unobserved cases were taken into account [ 28 ]. Nevertheless, we acknowledged that CFR could vary by population composition (e.g.…”

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

“…Consecutive patients with multiple myeloma and related precursor diseases with confirmed presence of SARS-CoV-2 between March 1, and April 30, 2020, from five large academic centers in New York City were included in this study. In the general population, the probability of dying from COVID-19 has been reported to be between 1% and 6% including all COVID-19–positive cases, and between 6% and 26% for patients hospitalized due to the virus ( 1 3 18 19 20 ). Here, we show that among 75 patients with multiple myeloma admitted due to COVID-19, the mortality rate was 29%, which is thought to be on the high end of what has been reported in the general population.…”

Delivery of hepato-pancreato-biliary surgery during the COVID-19 pandemic: an European-African Hepato-Pancreato-Biliary Association (E-AHPBA) cross-sectional survey

“…In December 2019, international awareness emerged of a new coronavirus that had been rapidly spreading through the Chinese city of Wuhan. 1 By late February 2020, it became clear that severe outbreaks of SARS-COV-2, as the virus had been named, had resulted in almost 3000 deaths in Italy. 2 By March 2020 the virus had spread to many other countries in Europe and much further globally, with over 10,000 new cases per day.…”